Summary of Ocular Therapeutix Q3 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: Ocular Therapeutix ended Q3 2025 with approximately $345 million in cash. This figure does not include about $445 million in net proceeds from an equity financing completed in October 2025, providing a cash runway into 2028.

Financial Flexibility: The company expressed confidence in its financial position, allowing for continued investment in clinical trials and preparation for potential commercialization of AXPAXLI.

2Strategic Updates and Business Highlights

AXPAXLI Development: The company is advancing its registrational studies for AXPAXLI, targeting wet age-related macular degeneration (AMD) and diabetic retinopathy (DR).

SOL-1 and SOL-R Trials: SOL-1 is on track for top-line data in Q1 2026, while SOL-R has reached its target randomization of 555 subjects, with expected data in H1 2027.

HELIOS Program: A new initiative for diabetic retinopathy, aiming for a broad label encompassing non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) through two superiority trials (HELIOS-2 and HELIOS-3).

Market Expansion Strategy: The company aims to expand the anti-VEGF market, currently valued at $15 billion, by targeting untreated patients and improving treatment adherence through AXPAXLI's long-lasting effects (up to 12 months).

3Forward Guidance and Outlook

Clinical Trials: The company anticipates top-line data from SOL-1 in Q1 2026 and SOL-R in H1 2027, with a focus on achieving a superiority label for AXPAXLI.

Regulatory Strategy: Ocular is pursuing a single broad superiority label for AXPAXLI in diabetic retinal diseases, which could significantly enhance market potential.

Long-term Studies: The SOL-X open-label extension study aims to provide additional long-term safety and efficacy data, further supporting AXPAXLI's market positioning.

4Bad News, Challenges, or Points of Concern

Market Competition: The retinal therapy market is becoming increasingly commoditized, with pricing pressures from biosimilars and existing anti-VEGF therapies. Ocular aims to differentiate AXPAXLI through its proposed superiority label.

Regulatory Risks: While the company is optimistic about its trial designs and endpoints, there is inherent uncertainty in clinical trial outcomes and regulatory approvals.

Patient Enrollment: Although the company has reported strong enrollment and retention rates, there are concerns about the willingness of NPDR patients to seek treatment, which could affect the HELIOS studies.

5Notable Q&A Insights

Label Expectations: Dr. Dugel indicated that the initial label for wet AMD is expected to include a superiority claim based on SOL-1 data, with flexible dosing options.

HELIOS Trials: There is confidence in achieving a broad label for DME based on historical precedents, with the expectation that successful trials will encompass both NPDR and DME without the need for separate studies.

Patient Engagement: The company has received positive feedback from payers regarding AXPAXLI's potential, highlighting its expected durability and the value of consistent therapy. Overall, Ocular Therapeutix is positioned strategically for growth with AXPAXLI, backed by a solid financial foundation and a robust clinical pipeline, while navigating competitive and regulatory challenges in the retinal therapy market.